癌症进展
癌癥進展
암증진전
Oncology Progress
2015年
5期
529-532
,共4页
谭敬安%陈焱君%陈瑞燕%林俊汕%曾宇婷
譚敬安%陳焱君%陳瑞燕%林俊汕%曾宇婷
담경안%진염군%진서연%림준산%증우정
良性前列腺增生%前列腺癌%表观扩散系数%PAP%P504S%PSA
良性前列腺增生%前列腺癌%錶觀擴散繫數%PAP%P504S%PSA
량성전렬선증생%전렬선암%표관확산계수%PAP%P504S%PSA
benign prostatic hyperplasia%prostatic cancer%apparent diffusion coefficient%PAP%P504S%PSA
目的:探讨良性前列腺增生和前列腺癌的ADC值与前列腺相关标志物PAP、P504S、PSA表达的关系。方法收集经病理证实的65例前列腺疾病患者,其中良性前列腺增生30例,前列腺癌35例。病理检查前3个月内均行前列腺MRI、DWI检查,采用单次激发EPI序列,b值为0 s/mm2和800 s/mm2,并采用免疫组化检测组织标本中PAP、P504S、PSA的表达,分析ADC值与PAP、P504S、PSA表达的关系。结果良性前列腺增生和前列腺癌的ADC值分别为(1.73±0.21)×10-3 mm2/s和(1.34±0.15)×10-3 mm2/s,差异具有统计学意义(t=8.545,P=0.000)。PAP和PSA在良性前列腺增生和前列腺癌中均表达,差异无统计学意义(P均>0.05),P504S在前列腺癌中的表达显著高于良性增生(Z=-7.055,P=0.000),双变量相关分析显示ADC值与P504S的表达呈显著负相(Spearman's相关系数r=-0.654,P=0.000);结论 PAP和PSA不能区别前列腺良恶性病变;P504S可以作为前列腺癌标志物;ADC值可以定量评价良性前列腺增生和前列腺癌,且与P504S存在负相关,可以作为前列腺良恶性病变MRI诊断的参考指标。
目的:探討良性前列腺增生和前列腺癌的ADC值與前列腺相關標誌物PAP、P504S、PSA錶達的關繫。方法收集經病理證實的65例前列腺疾病患者,其中良性前列腺增生30例,前列腺癌35例。病理檢查前3箇月內均行前列腺MRI、DWI檢查,採用單次激髮EPI序列,b值為0 s/mm2和800 s/mm2,併採用免疫組化檢測組織標本中PAP、P504S、PSA的錶達,分析ADC值與PAP、P504S、PSA錶達的關繫。結果良性前列腺增生和前列腺癌的ADC值分彆為(1.73±0.21)×10-3 mm2/s和(1.34±0.15)×10-3 mm2/s,差異具有統計學意義(t=8.545,P=0.000)。PAP和PSA在良性前列腺增生和前列腺癌中均錶達,差異無統計學意義(P均>0.05),P504S在前列腺癌中的錶達顯著高于良性增生(Z=-7.055,P=0.000),雙變量相關分析顯示ADC值與P504S的錶達呈顯著負相(Spearman's相關繫數r=-0.654,P=0.000);結論 PAP和PSA不能區彆前列腺良噁性病變;P504S可以作為前列腺癌標誌物;ADC值可以定量評價良性前列腺增生和前列腺癌,且與P504S存在負相關,可以作為前列腺良噁性病變MRI診斷的參攷指標。
목적:탐토량성전렬선증생화전렬선암적ADC치여전렬선상관표지물PAP、P504S、PSA표체적관계。방법수집경병리증실적65례전렬선질병환자,기중량성전렬선증생30례,전렬선암35례。병리검사전3개월내균행전렬선MRI、DWI검사,채용단차격발EPI서렬,b치위0 s/mm2화800 s/mm2,병채용면역조화검측조직표본중PAP、P504S、PSA적표체,분석ADC치여PAP、P504S、PSA표체적관계。결과량성전렬선증생화전렬선암적ADC치분별위(1.73±0.21)×10-3 mm2/s화(1.34±0.15)×10-3 mm2/s,차이구유통계학의의(t=8.545,P=0.000)。PAP화PSA재량성전렬선증생화전렬선암중균표체,차이무통계학의의(P균>0.05),P504S재전렬선암중적표체현저고우량성증생(Z=-7.055,P=0.000),쌍변량상관분석현시ADC치여P504S적표체정현저부상(Spearman's상관계수r=-0.654,P=0.000);결론 PAP화PSA불능구별전렬선량악성병변;P504S가이작위전렬선암표지물;ADC치가이정량평개량성전렬선증생화전렬선암,차여P504S존재부상관,가이작위전렬선량악성병변MRI진단적삼고지표。
Objective To investigate the correlation between apparent diffusion coefficient (ADC) and PAP, P504S, PSA expression in benign prostatic hyperplasia (BPH) and prostate cancer (Pca). Method 65 cases of pros-tate lesions confirmed pathologically were included in this study, in which there were 30 cases of BPH and 35 cases of Pca. DWI (b-values=0 s/mm2 and 800 s/mm2) images were obtained for all cases by Siemens Sonata 1.5T and the expression of PAP, P504S, PSA were detected with SP immunohistochemical technique individually. Result The mean ADC values of BPH and Pca were (1.73±0.21)×10-3 mm2/s and (1.34±0.15)×10-3 mm2/s, which were significantly different (t=8.545 ,P=0.000). The expression of PAP and PSA were both observed in BPH and Pca, with no signifi-cant difference appeared (both P>0.05). The expression of P504S in Pca was apparently higher than that in BPH (Z=-7.055, P=0.000), and the bivariate analysis showed that ADC was negatively correlated with P504S (Spearman ’s correlation coefficient r=-0.654, P=0.000). Conclusion PAP and PSA can't be applied in distinguishing benign and malignant lesions of prostate. P504S is supposed to be a specific biomarker for prostate cancer. ADC value is essen-tial in quantitatively evaluating the differences of BPH and Pca, and it negatively correlates with P504S, making it an important reference in MRI diagnosis of benign and malignant lesions of prostate.